key: cord-0028961-dyh80ln8
authors: Singh, Ravneet; Nasci, Victoria L.; Guthrie, Ginger; Ertuglu, Lale A.; Butt, Maryam K.; Kirabo, Annet; Gohar, Eman Y.
title: Emerging Roles for G Protein-Coupled Estrogen Receptor 1 in Cardio-Renal Health: Implications for Aging
date: 2022-03-07
journal: Biomolecules
DOI: 10.3390/biom12030412
sha: 29aa66dd5fb18c555e934c29fd6d136a2868520b
doc_id: 28961
cord_uid: dyh80ln8

Cardiovascular (CV) and renal diseases are increasingly prevalent in the United States and globally. CV-related mortality is the leading cause of death in the United States, while renal-related mortality is the 8th. Despite advanced therapeutics, both diseases persist, warranting continued exploration of disease mechanisms to develop novel therapeutics and advance clinical outcomes for cardio-renal health. CV and renal diseases increase with age, and there are sex differences evident in both the prevalence and progression of CV and renal disease. These age and sex differences seen in cardio-renal health implicate sex hormones as potentially important regulators to be studied. One such regulator is G protein-coupled estrogen receptor 1 (GPER1). GPER1 has been implicated in estrogen signaling and is expressed in a variety of tissues including the heart, vasculature, and kidney. GPER1 has been shown to be protective against CV and renal diseases in different experimental animal models. GPER1 actions involve multiple signaling pathways: interaction with aldosterone and endothelin-1 signaling, stimulation of the release of nitric oxide, and reduction in oxidative stress, inflammation, and immune infiltration. This review will discuss the current literature regarding GPER1 and cardio-renal health, particularly in the context of aging. Improving our understanding of GPER1-evoked mechanisms may reveal novel therapeutics aimed at improving cardio-renal health and clinical outcomes in the elderly.

The purpose of this review is to outline current understanding of GPER1-mediated actions and signaling pathways that may play a role in cardio-renal disease. In addition, we provide evidence of the potential novel role of GPER1 in the preservation of cardiovascular and renal health, particularly during aging.

Within the cardiovascular system, GPER1 is expressed in vascular beds, in both endothelial and vascular smooth muscle cells (VSMC) [48, 49, 55, [57] [58] [59] [60] . In the heart, GPER1 is expressed in mast cells [61] , cardiac fibroblasts, coronary artery endothelial cells [62] , coronary artery VSMCs [63] , and cardiomyocytes [64, 65] . Within the kidney, GPER1 is expressed in a variety of tubular epithelial cells in both the cortex and medulla [66, 67] . Additionally, GPER1 is expressed in renal interlobular arteries [68] and mesangial cells [69] .

GPER1 mRNA expression in kidney is higher in female rats than male rats [56, 70] . Importantly, aging increases myocardial GPER1 mRNA expression in male and female mice [71] . However, renal and aortic GPER1 mRNA expression is increased with aging in female, but not male, mice [71] , suggesting a potential female-specific role for GPER1 in regulating renal and vascular function during aging ( Figure 1 ). 

GPER1-related research has rapidly advanced following the discovery of a selective agonist and antagonists. G-1, a non-steroidal compound developed in 2007 by Bologa and colleagues, is a selective GPER1 agonist ( Figure 2 ) [72] . Studies utilizing GPER1 knockout (KO) mice have shown that G-1 activates GPER1 mediated signaling in wild type, but not KO mice [60, 73, 74] . Furthermore, in vitro studies have shown no binding affinity for G-1 to estrogen receptors α or β (ERα and ERβ) [72, 75] . G-1 modulates signaling pathways involved in the regulation of intracellular calcium [Ca 2+ ], phosphoinositide 3-kinase (PI3Ks), extracellular signal-related kinases (ERKs) and cyclic adenosine monophosphate (cAMP) [76, 77] .

GPER1-related research has rapidly advanced following the discovery of a selective agonist and antagonists. G-1, a non-steroidal compound developed in 2007 by Bologa and colleagues, is a selective GPER1 agonist ( Figure 2 ) [72] . Studies utilizing GPER1 knockout (KO) mice have shown that G-1 activates GPER1 mediated signaling in wild type, but not KO mice [60, 73, 74] . Furthermore, in vitro studies have shown no binding affinity for G-1 to estrogen receptors α or β (ERα and ERβ) [72, 75] . G-1 modulates signaling pathways involved in the regulation of intracellular calcium [Ca 2+ ], phosphoinositide 3-kinase (PI3Ks), extracellular signal-related kinases (ERKs) and cyclic adenosine monophosphate (cAMP) [76, 77] . GPER1 antagonists include G-15 and G-36 ( Figure 2 ). G-15 has been classified as a selective GPER1 antagonist with little binding to estrogen receptors (ERα and ERβ) and high binding affinity to GPER1 [78] . In COS7 and SKBr3 cells, G-15 inhibited G-1 and estradiol (E2)-mediated Ca 2+ mobilization and blocked activation of PI3K signaling through GPER1, but, despite slight binding, not ERα and ERβ [78] . G-36 has also been classified as a selective GPER1 antagonist. G-36 inhibited G-1 and E2 stimulated Ca 2+ mobilization and PI3K signaling through GPER1 and not ERα and ERβ in COS7 and SKBr3 cells similarly to G-15 [79] . G-36 was shown to bind more specifically to GPER1 than G-15. G-15 has been shown to display slight agonism towards ERα and ERβ activating estrogen response elements ~15%. G-36 on the contrary, displayed only ~5% activation of estrogen response elements displaying a more specific binding and specific antagonism of GPER1 signaling [79] .

Overall, G-1, G-15, and G-36 allow for important exploration of GPER1 involvement in other signaling mechanisms [79] . Further, the utilization of GPER1 KO mice has pro- GPER1 antagonists include G-15 and G-36 ( Figure 2 ). G-15 has been classified as a selective GPER1 antagonist with little binding to estrogen receptors (ERα and ERβ) and high binding affinity to GPER1 [78] . In COS7 and SKBr3 cells, G-15 inhibited G-1 and estradiol (E 2 )-mediated Ca 2+ mobilization and blocked activation of PI3K signaling through GPER1, but, despite slight binding, not ERα and ERβ [78] . G-36 has also been classified as a selective GPER1 antagonist. G-36 inhibited G-1 and E 2 stimulated Ca 2+ mobilization and PI3K signaling through GPER1 and not ERα and ERβ in COS7 and SKBr3 cells similarly to G-15 [79] . G-36 was shown to bind more specifically to GPER1 than G-15. G-15 has been shown to display slight agonism towards ERα and ERβ activating estrogen response elements~15%. G-36 on the contrary, displayed only~5% activation of estrogen response elements displaying a more specific binding and specific antagonism of GPER1 signaling [79] .

Overall, G-1, G-15, and G-36 allow for important exploration of GPER1 involvement in other signaling mechanisms [79] . Further, the utilization of GPER1 KO mice has provided another powerful tool to identify GPER1 actions under physiological and pathophysiological conditions.

The exact signaling mechanisms and transduction pathways of GPER1 are not completely understood, however, they are likely to be influenced by cell type, sex, site of action, and relative levels to other estrogen receptors. In this section, we will elaborate on the interaction between GPER1 signaling and other signaling pathways that play critical roles in the maintenance of cardio-renal health including the renin-angiotensin aldosterone system (RAAS), endothelin-1 (ET-1), nitric oxide (NO), reactive oxygen species (ROS), mitochondria, immunity, and inflammation.

The RAAS plays an important role in the cardio-renal system through regulation of blood pressure, fluid, and electrolyte homeostasis. The RAAS is activated in response to a sensed decrease in arterial blood pressure, decreased salt delivery to the distal convoluted tubule, and/or beta-adrenergic activation via sympathetic nerve input [80, 81] . Renin, which is stored in the juxtaglomerular cells of the kidney, is released following stimulus where it then converts angiotensinogen, from the liver, into angiotensin I. Angiotensin I is then converted into angiotensin II (ANG II) by angiotensin converting enzyme (ACE). ANG II stimulates an increase in blood pressure through several mechanisms, including vasoconstriction and sodium and water retention through aldosterone and antidiuretic hormone (ADH) [80, 81] . Aldosterone effects sodium handling by increasing the expression of epithelial sodium channel (ENaC) and sodium-potassium ATPase (Na/K ATPase) on the cell membrane in the collecting duct of the nephron [80, 81] . ADH affects water handling by inserting aquaporins on the cell membrane in the collecting duct of the nephron [80, 81] .

Dysfunction of the RAAS has been implicated in the pathophysiology of cardiovascular and kidney diseases. Importantly, there are sex differences in RAAS expression. Plasma renin levels are lower in females than males [82, 83] . In the hypertensive mRen2.Lewis rat, plasma renin levels are higher in males than females [84] . Plasma ACE levels are lower in young women than men, [85] however, there are no differences in these levels between genders in the middle and older ages [83, 86] . Interestingly, oral hormone replacement therapy in postmenopausal women reduces ACE levels [83, 87] . ANG II levels in normotensive premenopausal women are similar to those in men [83] . Data in the hypertensive mRen2.Lewis rat suggest that in pathological settings ANG II is higher in males compared to females [84] . Plasma aldosterone levels are reduced in premenopausal women compared to men and this difference is lost with menopause [83, 86] .

More importantly, there is a sex difference in the response to ANG II. Several studies show female mice have a reduced response to ANG II-induced blood pressure increase [88, 89] . Interestingly, a study by Sartori-Valinotti et al. showed that when treated with an ACE inhibitor, female Sprague Dawley rats had a more robust response to ANG II-induced blood pressure increase than males [90] . A high salt diet reversed this difference. While female Sprague Dawley rats had a relatively stable blood pressure on the high salt, male rats displayed a further increase in blood pressure to high salt [90] . Aortic rings from male spontaneously hypertensive rats have a larger vasoconstriction to ANG II than females [91] . In a human cohort, women and men had a similar blood pressure increase in response to ANG II, but men had a higher baseline blood pressure. In addition, ANG II infusion resulted in a reduced glomerular filtration rate in women compared to men, inferring a protection against increased glomerular pressure [86] . The apparent sex difference in RAAS effectors and the response to ANG II warrant a better understanding of various mediators that may be involved in the regulation and response to RAAS in cardio-renal health.

RAAS activation has also been implicated in age-associated arterial pro-inflammation and arterial remodeling [92, 93] . Pro-inflammatory overexpression of the effectors in the RAAS pathway, such as ANG II, angiotensinogen, ACE, and angiotensin receptor 1, pro-voke age-related cardiac and carotid remodeling in rodents [94] [95] [96] . Upregulation of ANG II, angiotensinogen, ACE, and angiotensin receptor 1 also participate in age-related remodeling of the aortic wall of both humans and nonhuman primates [74, 92, 97] . Interestingly, several studies from 1977-1994 reported a reduction of renin with age in the plasma of rats and humans [98] [99] [100] [101] [102] . This data conflicts with more current reports of elevated ANG II and other RAAS effectors, thus it is important to better understand how all components of RAAS may be impacted by age and how together the age-induced changes may influence cardio-renal health.

RAAS and GPER1 potentially intersect through concurrent effects on ANG II and other downstream pathways. GPER1 has been suggested to impact ANG II effects. In isolated aortic rings from ovariectomized (OVX) mRen2.Lewis rats, a model of estrogen and salt sensitivity, chronic G-1 treatment causes a reduction in ANG II-induced vasoconstriction [103] . In fact, G-1 treatment increased ACE2 expression and decreased ACE expression in these tissues, promoting a reduction in vascular tone [103] .

GPER1 has also been implicated in aldosterone-mediated responses. Aldosterone signals its effects via either the mineralocorticoid receptor (MR) or non-MR dependent pathways [104] . Evidence suggests that aldosterone contributes to GPER1 signaling in the vasculature [105] [106] [107] . However, it is unclear if this effect is through an interaction between the aldosterone signaling and GPER1 or if aldosterone can directly activate GPER1 [108] . GPER1 has been shown to play a role in aldosterone-mediated signaling in the kidney [66, 109, 110] . Cheng et al. showed that, in human embryonic kidney 293 cells, aldosterone did not bind GPER1 directly [66] . Thus, the effects of aldosterone on renal GPER1 signaling are likely through an interaction of aldosterone and GPER1 signaling pathways [66] . Recent studies report that GPER1 is necessary for non-MR aldosterone dependent pathways [111, 112] . Cheng et al. showed that in primary mouse collecting duct cells blockage of GPER1 with G-36 impairs the aldosterone mediated signaling cascade [109] . Gros et al. suggest that aldosterone may be an agonist for GPER1. While they did not test direct binding of aldosterone to GPER1, they used G-1 and G-15 to show that GPER1 is necessary for the non-MR-mediated vascular effects of aldosterone [111] . Additional research demonstrated that GPER1 predominantly stimulates the release of aldosterone in vascular endothelial cells [105, 106] .

Additional studies are needed to identify the interaction between GPER1 and aldosterone and to determine if this interaction is evident in a specific tissue-or cell-specific manner in males and females. Improving our understanding of how GPER1 impacts the RAAS system, particularly aldosterone non-MR signaling, could provide targets for management of blood pressure and water and electrolyte balance, which are often dysregulated with CV and renal diseases.

The endogenous peptide, ET-1 is a potent vasoconstrictor [113] . Within vascular endothelial cells, pre-pro-ET-1 precursor is cleaved in two steps by ET-1 converting enzymes, ECE-1 and ECE-2, to generate active ET-1 [113] . ET-1 actions are mediated by activation of its G protein-coupled receptors, ET A and ET B . Within the vasculature, ET A is primarily expressed in VSMCs [114] and mediates vasoconstriction, oxidative stress, and cell proliferation [115, 116] . ET B is primarily expressed in vascular epithelial and endothelial tissue as well as VSMCs [114] and mediates ET-1 clearance and vasodilation through the release of NO [115] [116] [117] [118] . Aging [119] [120] [121] [122] , menopause [123] , and the male sex [124, 125] are independently associated with higher plasma ET-1 levels, while the menstrual and pregnancy-induced rise in female gonadal hormones contribute to lowering plasma ET-1 levels [122, 124, [126] [127] [128] [129] .

These correlations invite curiosity for the role of estrogen signaling on the ET-1 system. Given that aging is a risk factor for hypertension [4] and ET-1 plays a critical role in the maintenance of blood pressure, ET-1 changes with age are thought to be in part responsible. Ovarian hormones have been shown to modulate the fluctuations in ET A and ET B responses in young pre-menopausal women [130] . In postmenopausal women, ET B -induced vasodilation is impaired compared to young women [131] . Lower serum levels of GPER-1 are associated with hypertension in postmenopausal women [132] , but the relationship between GPER-1 and age-related ET B dysfunction is unclear.

ET-1 signaling system has been implicated in GPER1-induced vascular effects. G-1 activation of GPER1 attenuates ET-1-mediated vasoconstriction and causes acute vasodilation in porcine coronary arteries [133] . G-1 increases VSMC [Ca 2+ ] i acutely [60] while GPER1 KO reduces VSMC [Ca 2+ ] i [134] . Additionally, G-1 reduces Ca 2+ spikes in VSMC [135] . GPER1 KO mice carotid arteries treated with ET-1 have a greater vasoconstriction response, but a reduced ET-1-stimulated VSMC [Ca 2+ ] i increase, suggesting that arteries lacking GPER1 are more sensitive to VSMC [Ca 2+ ] i [134] . ET A and ET B expression levels are indifferent in GPER1 KO carotid arteries [134] , which pinpoints GPER1 to be a potential regulator of VSMC [Ca 2+ ] i in order to balance the vasoconstrictive effects of ET-1.

In aortic tissue of male mice, acute inhibition of GPER1 by G-15 decreased ET B receptorstimulated NO bioactivity [57] . Overall, these studies suggest that GPER1 displays protective vascular effects. However, some data suggests that GPER1 is required for cardiac aging [136, 137] . An aging study comparing 2-year-old mice with age-matched GPER1 KO mice revealed that GPER1 caused the age-dependent upregulation of ET B and ECE-2 gene expression in myocardial tissue [137] . Whether global deletion of GPER1 may have had induced compensatory changes in other sex hormonal signaling pathways remains to be determined.

The renal ET-1 system promotes natriuresis [138, 139] and diuresis [140] , contributing to sodium homeostasis [141] . Renal ET-1 is most produced in the inner medullary collecting duct cells, which also have the highest expression of ET A and ET B , compared to other parts of the kidney [142] . More so, GPER1 receptor expression is greater in female rat kidney tissues, compared to males [56, 70] . We recently showed that activation of GPER1 within the renal medulla of female rats evokes natriuresis and diuresis [56, 143] . Specifically, we provided genetic and pharmacological evidence that both ET A and ET B collaborate to mediate GPER1-evoked natriuresis and diuresis [56, 143] . Furthermore, we showed that female GPER1 KO mice, but not males, have less ET-1, ET A , and ET B mRNA expression in kidney tissues [56] . These data suggest that estrogen's permissive actions on urinary sodium excretion via GPER1 activation is mediated through the renal ET-1 pathway. Sexspecific studies on young and aged hypertensive animal models will help trace the dynamic mechanistic relationship between GPER1 signaling and the ET-1 systems as it relates to sodium homeostasis and blood pressure regulation.

NO is a well-known vasodilator. Three isoforms of NO synthase (NOS) have been identified including: neuronal (nNOS; NOS1), inducible (iNOS; NOS2), and endothelial (eNOS; NOS3) [144] . These three isoforms utilize molecular oxygen, L-arginine, enzymes, and co-factors to generate NO [144] [145] [146] . NO signals primarily via the activation of soluble guanylyl cyclase and the generation of cyclic guanylyl guanosine monophosphate (cGMP) resulting in vasodilation [144] . Impaired NO signaling has been implicated in the pathophysiology of CV and renal diseases [147] [148] [149] [150] . NO signaling is thought to have sex specific expression differences and may play a role in male-female differences in cardio-renal health. NO release in response to acetylcholine is elevated in the aorta of female rats compared to males [151, 152] . Similarly, eNOS expression is higher in the kidney of female rats compared to males [153, 154] .

Several studies have suggested that NO production and release are reduced with age in rodents [155, 156] . Urinary excretion of NO metabolites, nitrite and nitrate, are reduced in aged rats compared to young [155, 156] . Similarly, the NO substrate L-arginine is reduced in the serum of aged rats compared to young [156] . The apparent decrease in NO level, inferred by reduced urinary excretion of NO metabolites and serum L-arginine, coincides with renal injury progression. Aged rats exhibit a reduced glomerular filtration rate and an increased renal vascular resistance and glomerular sclerosis [155, 156] . In addition, eNOS and nNOS expression decrease in the aging male rat kidney [156] [157] [158] .

NO bioavailability and activity are reduced in human populations with aging [159] [160] [161] . In a human study, vasodilation to acetylcholine in the brachial artery was reduced with age [161] . Asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, is increased in plasma in aged humans compared to young [159] . The increase in ADMA as well as the reduction in L-arginine are suspected to reduce NO bioavailability with age thus reducing NO-mediated vasodilation, potentially participating in the increased blood pressure associated with aging [159] [160] [161] .

Evidence suggests that GPER1 stimulates NO production and promotes relaxation in multiple vascular beds [162] [163] [164] [165] [166] . GPER1 activation by G-1 increases NO in endothelial cells leading to vascular relaxation [162, 164, 165] . Similarly, GPER1 expression is reduced in mesenteric arteries in aged female and young male Lewis rats compared to young female rats. This downregulation is associated with reduced vasorelaxation to estrogen and G-1 [167] . Moreover, GPER1 deletion in female mice attenuates NO bioactivity in carotid arteries [168] and promotes vasoconstriction of aortic rings in male mice [57] . Additionally, GPER1 KO promotes atherosclerosis in the aorta of female mice [168] . Several studies suggest that GPER1 is responsible for acute estrogen-dependent vasodilation in both male and female rat aortas, which involved an increase in NO levels and a decrease in blood pressure [169] [170] [171] possibly through mediation of eNOS-dependent NO formation [164, 167] . Contrary to the studies above, Meyer et al. showed that GPER1 deletion in male mice attenuates age-related impairment of NO-mediated relaxation [172] . The majority of the literature support GPER1 mediation of NO bioavailability as a potential protective mechanism in the vasculature, particularly in the cardio-renal systems. The interactions of NO and GPER1 could provide additional novel insights into physiologic and pathological changes in cardio-renal health with age and sex.

ROS constitute essential components of aerobic respiration and cell signaling and are delicately balanced with antioxidant systems under physiological conditions. Nevertheless, excess production of ROS, including superoxide (O 2 − ), hydroxyl radicals and hydrogen peroxide, leads to cellular toxicity in various disease states such as atherosclerosis, coronary ischemia, cardiac hypertrophy, and heart failure [173] as well as acute kidney injury (AKI) [174] and CKD [175] . Interestingly, there are sex differences in ROS profiles. Several studies in rats, humans, and human derived VSMCs showed that oxidative stress and markers such as lipid peroxidation are elevated in males compared to females [176] [177] [178] [179] . In addition to baseline differences there are apparent differences in oxidative stress in pathological settings. Female spontaneously hypertensive rats (SHR) exhibit a reduced blood pressure and reduced markers of oxidative stress compared to their male littermates [180] . Similarly, ANG II induces hypertension and oxidative stress to a lesser degree in female compared to male SHR [181] . Combined these studies indicate the importance of understanding how sex may influence oxidative stress. Moreover, progressive accumulation of oxidative damage is hypothesized to be the primary mechanism of aging, termed as oxidative stress theory of aging [182] . Thus, potential antioxidant mechanisms to target these processes are major topics under investigation [183] .

Emerging evidence suggests that GPER1 signaling regulates oxidative stress, a major player in the pathogenesis of aging and cardiovascular and renal disease [175, 184] . Several studies point to GPER1 as a crucial regulator of oxidative response. GPER1 is hypothesized to mediate the cardioprotective effects of estrogen through modulation of oxidative stress. In the mRen2 female rat model, GPER1 activation with G-1 is protective against saltinduced aortic remodeling. This protective effect is independent of changes in blood pressure, but associated with reduced lipid peroxidation, a marker of oxidative stress [185] .

In the same rat model, treatment with G-1 also significantly attenuates proteinuria and lipid oxidation in the renal cortex [67] . Bopassa et al. found that G-1 reduces myocardial infarct size and improves heart function after ischemia-reperfusion injury by inhibiting mitochondria permeability transition pore opening [186] . Acute oxidative stress opens the mitochondrial permeability transition pore, leading to cellular death, while inhibition of mitochondrial permeability transition pore opening confers protection against ischemic cardiac injury [186] .

In both male and female mice, KO of GPER1 results in left ventricular dysfunction and remodeling [65] , whereas pharmacological GPER1 activation mitigates the adverse effects of estrogen loss on left ventricular function in OVX rats [187] . Female GPER1 KO mice were also found to exhibit increased oxidative damage in cardiomyocytes and upregulation of oxidative stress-related genes along with cardiac dysfunction [188] . In turn, treatment with a mitochondria-targeted antioxidant effectively ameliorates cardiac dysfunction, suggesting that the cardioprotective effects of GPER1 may be mediated by its antioxidant action [188] . GPER1 activation has also been reported to provide renoprotection against methotrexate-induced oxidative stress in human renal epithelium cells [189] , neuroprotection against hydrogen peroxidase-induced apoptosis in primary mouse cortical neuronal culture [190] and cardio protection against doxorubicin-induced oxidative injury in male rats [191] . Furthermore, in a female mouse model of diabetes, activation of GPER1 attenuated oxidative stress in pancreatic β cells and promotes islet cell survival [73] .

On the contrary, there are a few studies suggesting that GPER1 may induce oxidative stress and cardiovascular toxicity. A study by Meyer et al. investigating genetic (GPER1 KO) or pharmacologic (G-36) inactivation of GPER1 in male mice suggests that GPER1 may play a role in cardiovascular aging and disease through promotion of ROS [136] . Vascular aging is characterized by increased O 2 − formation that impairs NO-dependent vasorelaxation [136] . Meyer et al. showed that aged GPER1 KO mice have less O 2 − formation in VSMC and were protected from age-related vasodilatory impairment compared to wild type aged mice. This is likely through a reduced NADPH oxidase 1 in response to GPER1 deletion [136] . Further, Meyer et al. demonstrated that GPER1 KO prevented endothelial aging in renal arteries of male mice [172] . Although abundant evidence suggests an important relationship between GPER1 and oxidative stress, the specific role of GPER1 activation in different pathophysiologic conditions and whether this role changes with increasing age remain to be investigated. Further research is necessary to clarify the role of GPER1 in regulating ROS and mitochondrial function. Understanding the mechanisms by which GPER1 could impact ROS could provide additional targets for therapeutics in the treatment of CV and renal diseases.

In the last decades, chronic inflammation has been acknowledged as a major driver of cardiovascular and renal disease [192] [193] [194] . Indeed, inflammation is the earliest step in the pathogenesis of atherosclerosis [195] and increased inflammatory cytokines are consistent predictors of the development and progression of cardiovascular disease [196] . Similarly, patients with CKD suffer from a chronic inflammatory state, which is associated with worse prognosis of the disease [197] . Furthermore, inflammation plays a major role in aging, a condition often referred to as inflammageing [198] . Indeed, inflammageing, characterized by a chronic pro-inflammatory state, affects almost all physiological systems and strongly correlates with cardiovascular and renal comorbidities [199] . GPER1 signaling appears to have an important role in regulation of inflammatory response in various systems, including the vasculature [200, 201] , adipose tissue [202] , gastrointestinal tract [203, 204] , and central nervous system [205] , as well as in pathologies such as cardiovascular disease [206] , nephrotoxicity [189] , and cancer [206] . Moreover, GPER1 mRNA is expressed in both early and mature cells of the immune system, suggesting that GPER1 has a functional role in maturation and function of immune cells [207] . GPER1 works to induce the expression of anti-inflammatory cytokine interleukin 10 and expand the regulatory T cell population [208, 209] , whereas GPER1 deficiency results in a proinflammatory state in animal models [202] . The different roles of GPER1 activation in each immune cell type have been discussed in depth elsewhere [207] . Overall, GPER1-induced immune modulation may have important implications for CV and renal health that should be noted. GPER1 appears to mediate anti-inflammatory effects in the vasculature and cardiac tissue. G-1 was shown to ameliorate tumor necrosis factor-induced upregulation of proinflammatory mediators in the endothelium in vitro [200] . Pre-treatment with G-1 also attenuates C-reactive protein-induced inflammatory response in macrophages and VSMC derived from young but not old female mice, suggesting that GPER1 s actions may be age-dependent [210] . Meyer et al. found that deletion of GPER1 in female mice leads to increased atherosclerosis progression and plasma cholesterol levels along with vascular inflammation, observed as a striking increase in macrophage and T cell accumulation in the aortic root [168] . Curiously, immune cell accumulation increases to the same extent with deletion of GPER1 or OVX, signifying that GPER1 was entirely responsible for the antiinflammatory effect of estrogen. Moreover, treatment of OVX mice with G-1 attenuates immune cell infiltration and atherosclerosis [168] , suggesting that GPER1 activation may be a therapeutic approach to target the increased cardiovascular risk in postmenopausal women. Wang et al. elucidated a role of GPER1 signaling on NLR Family Pyrin Domain Containing protein 3 (NLRP3) inflammasome activity. They found that cardiomyocyte-specific GPER1 deletion in mice is associated with upregulation of NLRP3 inflammasome-related genes. Importantly, NLRP3 inhibition significantly improves heart function ameliorated by GPER1 deletion [211] , suggesting that GPER1 signaling may be crucial to regulate NLRP3 inflammasome in cardiac tissue.

GPER1 activation appears to have anti-inflammatory effects in the renal system as well [212] . Estrogen has been proposed to be protective against kidney disease in premenopausal women [56] . GPER1 appears to also play a role in estrogen-mediated cytoprotection due to its high expression in the renal tubular cells [56] . Using methotrexate-induced nephrotoxicity models in human renal epithelial cells, Kurt et al. showed that co-incubation of cells with either E 2 or G-1 reduces the high levels of interleukin-1β and interleukin-6 induced by methotrexate [189] . However, our studies indicate that although G-1 treatment effectively prevented salt-induced proteinuria and proximal tubular injury in female Dahl salt sensitive rats, it did not decrease salt-induced immune cell accumulation in the kidney [213] . These results highlight the need for further research to confirm the immune effects of GPER1 activation in cardiovascular and renal systems and to elucidate the potential role of GPER1 signaling in inflammageing. A better understanding of the mechanisms by which GPER1 could impact inflammation and immune infiltration could provide additional targets for therapeutics in the treatment of CV and renal diseases.

Overall, GPER1 signaling has a clear role in RAAS, ET-1, NO, ROS, mitochondria, immunity, and inflammation signaling pathways that play critical roles in cardio-renal health (Figure 3 ). These interactions are not completely understood, but each present an opportunity for improvement of cardio-renal health. 

Several lines of research implicate an important role for GPER1 signaling pathway in different cardiorenal disease pathologies. In the current section, we will highlight th potential role of GPER1 in hypertension, cardiac and kidney diseases.

Hypertension, also known as the "silent killer", is a leading risk factor fo cardiovascular disease. It is responsible for about 9.5 million deaths per year worldwid [214, 215] . According to Centers for Disease Control and Prevention (CDC) data, th prevalence of hypertension is higher in the older population (>60 years old, 74.5%). Whil the overall prevalence of hypertension in younger adults (18-39 years old) is 22.4%, ther is a higher prevalence of hypertension in men (31.2%) than in women (13.0%) [216] . Thi sex difference decreases with age, with a similar prevalence in men and women by th age of 60 [216] . Risk factors of hypertension include unhealthy diets (high sodium or low potassium), physical inactivity, consumption of tobacco and alcohol, and obesity [217 Despite the proven pervasiveness of hypertension particularly among older adults, man challenges remain today in the treatment and prevention of hypertension clinically.

Studies point to GPER1 as a novel regulator for blood pressure and sodium homeostasis. GPER1 activation with G-1 acutely reduces blood pressure in male Spragu 

Several lines of research implicate an important role for GPER1 signaling pathways in different cardiorenal disease pathologies. In the current section, we will highlight the potential role of GPER1 in hypertension, cardiac and kidney diseases.

Hypertension, also known as the "silent killer", is a leading risk factor for cardiovascular disease. It is responsible for about 9.5 million deaths per year worldwide [214, 215] . According to Centers for Disease Control and Prevention (CDC) data, the prevalence of hypertension is higher in the older population (>60 years old, 74.5%). While the overall prevalence of hypertension in younger adults (18-39 years old) is 22.4%, there is a higher prevalence of hypertension in men (31.2%) than in women (13.0%) [216] . This sex difference decreases with age, with a similar prevalence in men and women by the age of 60 [216] . Risk factors of hypertension include unhealthy diets (high sodium or low potassium), physical inactivity, consumption of tobacco and alcohol, and obesity [217] . Despite the proven pervasiveness of hypertension particularly among older adults, many challenges remain today in the treatment and prevention of hypertension clinically.

Studies point to GPER1 as a novel regulator for blood pressure and sodium homeostasis. GPER1 activation with G-1 acutely reduces blood pressure in male Sprague Dawley rats [60] . Chronic systemic treatment with G-1 also lowers blood pressure in OVX Sprague Dawley rats [56] and OVX mRen2.Lewis rats [103] . In addition, increased blood pressure is observed in female GPER1 KO mice by 9 months of age [48] and women with a hypoactive GPER1 variant [218] . GPER1 s blood pressure lowing actions are multifactorial and involve regulating the vascular tone. G-1 promotes vasodilation in different vascular beds, including coronary arteries [60, 133] , carotid arteries [133] , aorta, and mesenteric arteries [170] . Dilation downstream of GPER1 activation involves multiple signaling pathways including NO [162, 166, 167, 169] , ET-1 system [133] , and the RAAS pathway [103, [105] [106] [107] 111, 112] , depending on the capillary bed and species. Determining whether G-1-induced vasodilation is sex-specific has been controversial. Debortoli et al. showed greater G-1-induced vasodilation response in female Wister rats compared to males [219] and in isolated arteries from postmenopausal women compared to age-matched men [220] . However, other studies have shown no sex differences in GPER1-induced vasodilation in rat mesenteric arteries [165, 221] , carotid arteries [171] , and cerebral arterioles [222] .

Recently, we showed that renal medullary GPER1 activation promotes ET-1 dependent natriuresis in female, but not male, rats, which may also contribute to GPER1 blood pressure lowering actions [56, 143] . GPER1-mediated estrogen action along the nephron is still unclear. In distal convoluted tubule cells, estrogen increases NaCl cotransporter phosphorylation [223] . Of note, GPER1 is required for E 2 -induced spike in Ca 2+ in the distal renal tubules [224] . Importantly, GPER1 is heavily expressed along the distal convoluted tubule cells basolateral membrane [223] .

In women, GPER1 hypofunctional variant is associated with increased blood pressure [218] and increased plasma low-density lipoprotein cholesterol [225] . In addition, a study by Liu et al. suggested that serum GPER1 is a protective factor against hypertension in menopausal women, but not premenopausal women [132] . Improving our understanding about signaling pathways mediating GPER1 s blood pressure lowering actions is clinically important for drug development, especially for preventing postmenopausal hypertension.

Heart disease is the number one leading cause of death in the US [226] . CDC data reported 696,962 deaths from heart disease in 2020, which is about 1 in 4 deaths [2] . According to the data of the American Heart Association, the number of men with a diagnosed heart attack or fatal coronary heart disease (CHD) is higher than women [4] . In addition, the prevalence of heart attack and CHD increases with aging, independent of sex [4] . Risk factors for heart disease include high blood pressure, dyslipidemia, diabetes mellitus, and obesity [4, 227] . Advanced measures are required to avoid heart disease and provide better care for the impacted population.

Previous studies have provided evidence for the cardioprotective role of GPER1 activation against heart failure in male mice [228] and myocardial inflammation in male SHR [76] . In addition, it was reported that GPER1 activation mitigates doxorubicin-induced cardiotoxicity in male rats, [191] , protects against cardiomyocyte death [64, 229] , improves myocardial mechanical performance, and reduces infarct size in isolated rat and mouse hearts after ischemia reperfusion injury through the involvement of PI3K kinase/AKT signaling pathway [72, [230] [231] [232] . Further, GPER1 deletion in female mice led to cardiac remodeling and oxidative stress [188] . G1 decreases cardiac remodeling induced by salt [233] and hypertrophic regulators like ANG II and ET-1 [77] . G-1 also inhibits cell cycle gene expression including cyclin B1 and CDK1 which are involved in cardiac fibroblast and mast cell proliferation and interstitial remodeling [77] . However, the exact signaling actions and transduction pathways of cardiac GPER1 are not completely understood.

Estrogen-induced regulation of heart rate appears to be linked to GPER1 rather than ERα and Erβ [234, 235] . In addition, GPER1 has been shown to modulate maternal estrogen levels in zebrafish, which are essential for appropriate embryonic heart rates [235] . Overall, GPER1 signaling is important in maintenance of cardiac health and a potential therapeutic target in heart disease.

Acute kidney injury (AKI) is a pathological condition characterized primarily by a rapid increase in serum creatinine over a short period of time [236] . AKI causes around 1.7 million global deaths annually and affects more than 13.3 million people globally [237] . Men have a higher incidence of AKI-dialysis compared to women [238] . Further, aging is associated with increased incidence of AKI [239] [240] [241] . Risk factors for AKI include kidney ischemia reperfusion and reduced blood flow leading to renal hypoxia [242] . Renal hypoxia can lead to tissue damage [242, 243] and this can cause fluid and waste built up resulting in life-threatening complications, or even death if left untreated [244] . Therefore, more preventive measures are required to avoid complications and provide better care for people impacted by AKI.

Previous studies have reported an important role of E 2 signaling in the regulation of eNOS expression in rat kidneys, which provides protection against ischemia reperfusioninduced AKI [245] . Moreover, Wu et al. reported that E 2 accelerates the regeneration of renal tubules in male rats after ischemia reperfusion-induced AKI through reducing inflammation [246] . Furthermore, GPER1 has been shown to have protective effects against ischemia reperfusion injury in the rat and human heart [64, 186, 232, 247] . To date, the contribution of GPER1 in AKI is not completely clear, however, a better understanding of its role could reveal novel avenues for therapeutic intervention.

Damage in the structure and/or function of the kidney often leads to CKD, which is characterized by its irreversibility and slow progression [5] . An estimated 15% of US adults (37 million people) have CKD [9] . CKD is more common in the older population (>65 years old, 38.1%) than the younger population (18-44 years old, 6.0%). CDC data reports a slightly higher percentage of CKD prevalence in women (14.3%) than men (12.4%) during their life span [9] .

Interestingly, GPER1 activation has been shown to reduce kidney damage in mRen2.Lewis rats that were fed a high-salt diet [67] . Earlier studies reported that ovariectomy increases levels of renal inflammatory markers in Dahl salt-sensitive female rats [248] , hinting at the protective role of the female sex hormone against hypertension and end-organ kidney damage. Moreover, we reported that G-1 ameliorates kidney damage in high salt-fed female Dahl salt-sensitive via preservation of the proximal tubule brush border integrity [213] . The definitive role of GPER1 in CKD initiation and progression is not entirely known yet, but evidence supports its role as a protective mechanism against kidney damage, independent from blood pressure changes.

Collectively, evidence suggests GPER1 is protective in hypertension, heart, and kidney disease (Figure 3) . A more in depth understanding of the complex pathway interactions and signaling mechanisms are therefore imperative in furthering cardio-renal health. In addition, cardio-renal diseases often share many risk factors and comorbidities therefore understanding the complex interactions and overlap of these signaling pathways and GPER1 s potential role could lead to benefits in many aspects of human health. One such avenue is in cancer research. Patients with CV and renal diseases have a higher incidence of malignancies [249] [250] [251] [252] [253] [254] [255] [256] [257] . Conversely, studies point to increased risk for CV and renal complications in cancer survivors [258] [259] [260] [261] . In addition, some therapeutic regimens used for treatment of breast and prostate cancer pose potential cardiac and nephrotoxic risk [260, 262] . Given the role of GPER1 signaling in cardiorenal disease and carcinogenesis, improving our understanding of the cardiovascular and renal responses to GPER1 will open another avenue to improve the care provided to cancer patients.

Future studies aimed at better understanding the impact of GPER1 on cardio-renal disease mechanisms during aging could reveal novel therapeutics aimed at improving clinical outcomes. RAAS, NO, ET-1, ROS, inflammation, and immune infiltration have all been implicated in CV and renal disease. Furthermore, there have been described changes in each of these pathways with age and sex bolstering support for understanding mechanisms that could be impacted by sex hormones. GPER1 is one such mechanism that could provide protection against age-related CV and renal disease development and progression. Recently Sharma et al. investigated the preclinical potential of G-1 in mouse models of obesity and diabetes [263] . While there may be a therapeutic promise for G-1 in metabolic disease, it is unknown if this promise could extend to cardio-renal disease. In clarifying the mechanisms by which GPER1 interacts with these signaling systems, novel therapeutics for management of cardiovascular and renal disease could be developed. Ultimately additional work needs to be done still to fully understand the potential of GPER1 in regulating mechanisms of cardio-renal health in elderly.

The Top 10 Causes of Death

Mortality in the United States

Cardio-renal syndromes: A systematic approach for consensus definition and classification

Heart Disease and Stroke Statistics-2021 Update

USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disaeases

GHE: Life Expectancy and Healthy Life Expectancy

Fact sheet: Aging in the United States

Crude Percentage with Cardiovascular Disease among All Adults by Age

Chronic Kidney Disease in the United States, 2021; US Department of Health and Human Services

The Critical Role of Metabolic Pathways in Aging

Understanding ageing from an evolutionary perspective

The Hallmarks of Aging. Cell

Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series

Aortic Root Remodeling and Risk of Heart Failure in the Framingham Heart Study

Age-related atrial fibrosis

The aging heart

Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney

Glomerular number and size in relation to age, kidney weight, and body surface in normal man

Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors

Estimation of total glomerular number in stable renal transplants

Glomerular density in renal biopsy specimens predicts the long-term prognosis of iga nephropathy

Glomerular function, structure, and number in renal allografts from older deceased donors

Effects of aging on glomerular function and number in living kidney donors

Why do men get more heart disease than women? an international perspective

Gender differences in cardiovascular disease and comorbid depression

Gender differences in cardiovascular disease

Gender differences in coronary heart disease

The Menopausal Transition: Analysis of LH, FSH, Estradiol, and Progesterone Concentrations During Menstrual Cycles of Older Women

Sex Hormones and Age: A Cross-sectional Study of Testosterone and Estradiol and Their Bioavailable Fractions in Community-dwelling Men

Testosterone and Cardiovascular Disease

Clinical review: Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis

Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study

Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study

Testosterone Supplementation in Male Obese Zucker Rats Reduces Body Weight and Improves Insulin Sensitivity but Increases Blood Pressure

Adverse Events Associated with Testosterone Administration

Cardiovascular and Metabolic Consequences of Testosterone Supplements in Young and Old Male Spontaneously Hypertensive Rats: Implications for Testosterone Supplements in Men

Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring

Effects of hormonal replacement therapy in postmenopausal hypertensive patients

Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mren2.lewis rat

Ovariectomy augments hypertension in aging female dahl salt-sensitive rats

Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives

Minireview: G protein-coupled estrogen receptor-1, gper-1: Its mechanism of action and role in female reproductive cancer, renal and vascular physiology

G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: A new player in cardiovascular and metabolic oestrogenic signalling

Extra-nuclear estrogen receptor GPR30 regulates serotonin function in rat hypothalamus

Role of estrogen receptors and g protein-coupled estrogen receptor in regulation of hypothalamus-pituitary-testis axis and spermatogenesis

Expression pattern of g protein-coupled receptor 30 in lacz reporter mice

Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice

Searching for a role in estrogen physiology

Estrogens-new players in spermatogenesis

Estrogen, a female hormone involved in spermatogenesis

Activation of GPR30 improves exercise capacity and skeletal muscle strength in senescent female Fischer344 × Brown Norway rats

Protein-Coupled Estrogen Receptor, GPER1, Offers a Novel Target for the Treatment of Digestive Diseases. Front

Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells

Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and gpr30 in arteries and veins of patients with atherosclerosis

Evidence for G-Protein-Coupled estrogen receptor as a pronatriuretic factor

Deletion of G Protein-Coupled estrogen receptor increases endothelial vasoconstriction

Cloning of cDNAs encoding g protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress

The GPER1 agonist g-1 attenuates endothelial cell proliferation by inhibiting dna synthesis and accumulating cells in the s and g2 phases of the cell cycle

Regulatory Role of G Protein-Coupled Estrogen Receptor for Vascular Function and Obesity

GPR30 decreases cardiac chymase/angiotensin II by inhibiting local mast cell number

Estrogen Inhibits LDL (Low-Density Lipoprotein) Transcytosis by Human Coronary Artery Endothelial Cells via GPER (G-Protein-Coupled Estrogen Receptor) and SR-BI (Scavenger Receptor Class B Type 1)

Activation of GPER Induces Differentiation and Inhibition of Coronary Artery Smooth Muscle Cell Proliferation

Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats

Cardiomyocyte-specific deletion of the G protein-coupled estrogen receptor (GPER) leads to left ventricular dysfunction and adverse remodeling: A sex-specific gene profiling analysis

Anatomical location and redistribution of G protein-coupled estrogen receptor-1 during the estrus cycle in mouse kidney and specific binding to estrogens but not aldosterone

Estrogen Receptor GPR30 Reduces Oxidative Stress and Proteinuria in the Salt-Sensitive Female mRen2.Lewis Rat

G protein-coupled estrogen receptor activation improves contractile and diastolic functions in rat renal interlobular artery to protect against renal ischemia reperfusion injury

Role of G protein-coupled estrogen receptor 1 in modulating transforming growth factor-β stimulated mesangial cell extracellular matrix synthesis and migration

Estrogen receptor profiles across tissues from male and female Rattus norvegicus

Alterations in the estrogen receptor profile of cardiovascular tissues during aging

Virtual and biomolecular screening converge on a selective agonist for GPR30

Importance of extranuclear estrogen receptor-α and membrane g protein-coupled estrogen receptor in pancreatic islet survival

Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1

Protein-Coupled receptor 30 (gpr30) mediates gene expression changes and growth response to 17β-estradiol and selective gpr30 ligand g-1 in ovarian cancer cells

The activation of the G protein-coupled estrogen receptor (GPER) prevents and regresses cardiac hypertrophy

Female Heart Health: Is GPER the Missing Link?

In vivo effects of a GPR30 antagonist

Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity

Potential effects of renin activation on the regulation of renin production

Renin angiotensin system and gender differences in the cardiovascular system

Gender and the renin-angiotensin-aldosterone system

Sex differences in circulating and renal angiotensins of hypertensive mRen(

Gender Differences in Angiotensin-Converting Enzyme (ACE) Activity and Inhibition by Enalaprilat in Healthy Volunteers

Impact of gender on the renal response to angiotensin II

Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women

Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice

Sex differences in the development of angiotensin II-induced hypertension in conscious mice

Sex Differences in the Pressor Response to Angiotensin II When the Endogenous Renin-Angiotensin System Is Blocked

A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats

Aging Increases Aortic MMP-2 Activity and Angiotensin II in Nonhuman Primates

Proinflammation: The key to arterial aging

Involvement of NADPH oxidase in age-associated cardiac remodeling

Angiotensin II activates matrix metalloproteinase type ii and mimics age-associated carotid arterial remodeling in young rats

Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function

Proinflammatory Profile Within the Grossly Normal Aged Human Aortic Wall

Aging and the renin-angiotensin system

Renin-angiotensin system, converting-enzyme inhibition and kidney function in aging female rats

Changes in the Renin-Angiotensin-Aldosterone Axis in Later Life

Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: Studies in normal subjects and patients with essential hypertension

Age and the Renin-Aldosterone System

Chronic treatment with the g protein-coupled receptor 30 agonist g-1 decreases blood pressure in ovariectomized mren2.lewis rats

Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions

Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation

GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells

Diabetes impairs the vascular effects of aldosterone mediated by G protein-coupled estrogen receptor activation

Rapid actions of aldosterone revisited: Receptors in the limelight

Rapid Aldosterone-Mediated Signaling in the DCT Increases Activity of the Thiazide-Sensitive NaCl Cotransporter

Aldosterone rapidly activates p-PKC delta and GPR30 but suppresses p-PKC epsilon protein levels in rat kidney

GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone

Unraveling the mechanisms underlying the rapid vascular effects of steroids: Sorting out the receptors and the pathways

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

Expression and function of ETA and ETB receptors in SSc

Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin. Can

Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1

Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETBreceptors

Clearance of circulating endothelin-1 by etb receptors in rats

Anatomic heterogeneity of vascular aging: Role of nitric oxide and endothelin

Expression of endothelin, fibronectin, and mortalin as aging and mortality markers

Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: Implications for atherosclerosis

Endothelin in the female vasculature: A role in aging?

endothelial function is impaired across the stages of the menopause transition in healthy women

influence of sex hormones on plasma endothelin levels

Age-and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects

Changes in plasma and amniotic fluid endothelin levels during pregnancy: Facts or artefacts?

Changes in maternal plasma levels of VEGF, bFGF, TGF-beta1, ET-1 and sKL during uncomplicated pregnancy, hypertensive pregnancy and gestational diabetes

Maternal and fetal circulating sKL and ET-1 levels as function of normal labor at term

Modulation of plasma endothelin levels by the menstrual cycle

Ovarian hormones modulate endothelin-1 receptor responses in young women

ETBreceptor contribution to vascular dysfunction in postmenopausal women

GPER was associated with hypertension in post-menopausal women

Dilation of epicardial coronary arteries by the g protein-coupled estrogen receptor agonists g-1 and ici 182,780

GPER regulates endothelin-dependent vascular tone and intracellular calcium

The G Protein-Coupled Estrogen Receptor 1 (GPER1/GPR30) Agonist G-1 Regulates Vascular Smooth Muscle Cell Ca 2+ Handling

Obligatory role for GPER in cardiovascular aging and disease

GPER is required for the age-dependent upregulation of the myocardial endothelin system

Contribution of endothelin a receptors in endothelin 1-dependent natriuresis in female rats

Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention

Cooperative role of ETAand ETBreceptors in mediating the diuretic response to intramedullary hyperosmotic NaCl infusion

Nitric oxide and the A and B of endothelin of sodium homeostasis

Sex differences in ET-1 receptor expression and Ca 2+ signaling in the IMCD

Functional Interaction of Endothelin Receptors in Mediating Natriuresis Evoked by G Protein-Coupled Estrogen Receptor 1

Nitric oxide synthases: Regulation and function

Modular Structure of Neuronal Nitric Oxide Synthase: Localization of the Arginine Binding Site and Modulation by Pterin

Structure of Nitric Oxide Synthase Oxygenase Dimer with Pterin and Substrate

Nitric oxide signalling in cardiovascular health and disease

Nitric oxide signalling in kidney regulation and cardiometabolic health

Nitric oxide status in patients with chronic kidney disease

Role of Nitric Oxide in the Cardiovascular and Renal Systems

Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae

Gender Difference in Endothelial Dysfunction in the Aorta of Spontaneously Hypertensive Rats

Gender Differences in the Renal Nitric Oxide (NO) System

Sex hormones and renal nitric oxide synthases

Basal and stimulated nitric oxide in control of kidney function in the aging rat

Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging

Tubulointerstitial disease in aging: Evidence for underlying peritubular capillary damage, a potential role for renal ischemia

Sexual dimorphism in the aging kidney: Effects on injury and nitric oxide system

Blood Pressure, and Renal Perfusion in Elderly Subjects

Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly

Age-Related Reduction of NO Availability and Oxidative Stress in Humans

Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling

Sex Differences in the Vasodilation Mediated by G Protein-Coupled Estrogen Receptor (GPER) in Hypertensive Rats

Role of GPER in estrogen-dependent nitric oxide formation and vasodilation

GPER agonist dilates mesenteric arteries via PI3K-Akt-eNOS and potassium channels in both sexes

Pregnancy Augments G Protein Estrogen Receptor (GPER) Induced Vasodilation in Rat Uterine Arteries via the Nitric Oxide-cGMP Signaling Pathway

Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation

Protein-coupled Estrogen Receptor Protects from

GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure

Vasodilation in Response to the GPR30 Agonist G-1 is Not Different from Estradiol in the mRen2.Lewis Female Rat

Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries

Mediates Functional Endothelial Aging in Renal Arteries

Role of oxidative stress in cardiovascular diseases

Oxidative stress as a potential target in acute kidney injury

Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease

Gender difference in oxidative stress: A new look at the mechanisms for cardiovascular diseases

Myocardial antioxidant and oxidative stress changes due to sex hormones

Greater Oxidative Stress in Healthy Young Men Compared with Premenopausal Women

Gender Disparity in Susceptibility to Oxidative Stress and Apoptosis Induced by Autoantibodies Specific to RLIP76 in Vascular Cells

Gender differences in superoxide generation in microvessels of hypertensive rats: Role of NAD(P)H-oxidase

Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats

Oxidative stress, aging, and diseases

Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities

Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients

GPER activation ameliorates aortic remodeling induced by salt-sensitive hypertension

A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury

Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats

G protein-coupled estrogen receptor (GPER) deficiency induces cardiac remodeling through oxidative stress

The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells

Neuroprotective effects of oestrogen against oxidative toxicity through activation of G-protein-coupled receptor 30 receptor

Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease

Oxidative Stress Is Progressively Enhanced with Advancing Stages of CKD

Plasma protein thiol oxidation and carbonyl formation in chronic renal failure

Atherosclerosis and inflammation: Overview and updates

Inflammation and Cardiovascular Diseases: The Most Recent Findings

Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study

Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty

Inflamm-ageing: The role of inflammation in age-dependent cardiovascular disease

G-Protein Coupled Receptor 30 (GPR30): A Novel Regulator of Endothelial Inflammation

G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity

GPER Deficiency in Male Mice Results in Insulin Resistance, Dyslipidemia, and a Proinflammatory State

Protein-Coupled Receptor 30 (GPR30) Expression Pattern in Inflammatory Bowel Disease Patients Suggests its Key Role in the Inflammatory Process. A Preliminary Study

G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease

γδ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury

GPER (GPR30): A Nongenomic Receptor (GPCR) for Steroid Hormones with Implications for Cardiovascular Disease and Cancer

Protein-Coupled Estrogen Receptor in Immune Cells and Its Role in Immune-Related Diseases

The G Protein-coupled Estrogen Receptor (GPER) Agonist G-1 Expands the Regulatory T-cell Population Under TH17-polarizing Conditions

Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1

Estrogen Effects on Vascular Inflammation Are Age Dependent: Role of estrogen receptors. Arteriosclerosis, thrombosis, and vascular biology

NLRP3 inhibition improves heart function in GPER knockout mice

Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1

Activation of G protein-coupled estrogen receptor 1 ameliorates proximal tubular injury and proteinuria in Dahl salt-sensitive female rats

Mortality patterns in hypertension

Hypertension Prevalence Among Adults Aged 18 and Over: United States

A common hypofunctional genetic variant of GPER is associated with increased blood pressure in women

GPER modulates tone and coronary vascular reactivity in male and female rats

Vasodilatory effects of the selective GPER agonist G-1 is maximal in arteries of postmenopausal women

Sex difference in GPER expression does not change vascular relaxation or reactive oxygen species generation in rat mesenteric resistance arteries

G Protein-Coupled Estrogen Receptor Agonist Improves Cerebral Microvascular Function After Hypoxia/Reoxygenation Injury in Male and Female Rats

Ovarian hormones and prolactin increase renal NaCl cotransporter phosphorylation

Praetorius, J. 17β-Estradiol induces nongenomic effects in renal intercalated cells through G protein-coupled estrogen receptor 1

Protein Estrogen Receptor as a Regulator of Low-Density Lipoprotein Cholesterol Metabolism: Cellular and population genetic studies

Deaths: Final Data for 2019. Natl. Vital Stat. Rep. 2021, 70, 8. 227. Center for Disease Control and Prevention. Know Your Risk for Heart Disease

Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: Insights into cellular mechanisms

Activation of novel estrogen receptor GPER results in inhibition of cardiocyte apoptosis and cardioprotection

Activation of G protein-coupled oestrogen receptor 1 at the onset of reperfusion protects the myocardium against ischemia/reperfusion injury by reducing mitochondrial dysfunction and mitophagy

Protein-Coupled Estrogen Receptor 1 Mediates Acute Estrogen-Induced Cardioprotection via MEK/ERK/GSK-3β Pathway after Ischemia/Reperfusion

Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury

Attenuation of Salt-Induced Cardiac Remodeling and Diastolic Dysfunction by the GPER Agonist G-1 in Female mRen2.Lewis Rats

The Effects of 17α-Ethinylestradiol on the Heart Rate of Embryonic Japanese Medaka (Oryzias latipes)

G protein-coupled estrogen receptor regulates embryonic heart rate in zebrafish

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury

Sex differences in acute kidney injury requiring dialysis

Incidence of acute kidney injury and its association with mortality in patients with COVID-19: A meta-analysis

Acute Kidney Injury in the Elderly

Acute Kidney Injury in Elderly Persons

Hypoxia Inducible Factor 1-Alpha (HIF-1 Alpha) Is Induced during Reperfusion after Renal Ischemia and Is Critical for Proximal Tubule Cell Survival

Human Nephrosclerosis Triggers a Hypoxia-Related Glomerulopathy

Acute Kidney Injury: Advances in Definition, Pathophysiology, and Diagnosis

Estradiol attenuates ischemia reperfusion-induced acute kidney injury through PPAR-γ stimulated eNOS activation in rats

17β-Estradiol Accelerated Renal Tubule Regeneration in Male Rats After Ischemia/Reperfusion-Induced Acute Kidney Injury

G-protein coupled estrogen receptor 1 expression in rat and human heart: Protective role during ischaemic stress

Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats

Incidence of cancer in patients with chronic heart failure: A long-term follow-up study

Patients with Heart Failure Have an Increased Risk of Incident Cancer

Heart Failure after Myocardial Infarction Is Associated with Increased Risk of Cancer

Associated Risk of Malignancy in Patients with Cardiovascular Disease: Evidence and Possible Mechanism

Cancer risk following organ transplantation: A nationwide cohort study in Sweden

Cancer Incidence Before and After Kidney Transplantation

Cancer in patients on dialysis for end-stage renal disease: An international collaborative study

CKD and the Risk of Incident Cancer

Cardiovascular disease after cancer therapy

Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study

The intersections between the kidney and cancer

The link between kidney disease and cancer: Complications and treatment

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes